State Ledger
Company profile

Neuphoria Therapeutics Inc. CIK 1191070

Ticker
NEUP (Nasdaq)
Industry
Pharmaceutical Preparations
Headquarters
Burlington, MA 01803
Fiscal year end
2026 (FY)
Market Data
Close
$3.35
Change
+$0.00
Change %
0.00%
Volume
0

NEUP · trading date Oct 9, 2026 · previous close $3.35 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
$1.17M
Net income
-$13.45M
Total assets
$28.71M
Total liabilities
$4.11M
Stockholders' equity
$24.60M
Cash & equivalents
$19.87M
Operating income
-$16.45M
Operating cash flow
-$12.35M
Capital expenditures
—

Fiscal year 2026, via 10-K filed 2026-09-18. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
-1,401.1%
Net margin
-1,145.7%
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
14.3%
Equity / assets
85.7%
CapEx / revenue
—
Operating cash flow / net income
0.92×

Derived from the fiscal year 2026 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2026 $1.17M -$13.45M $28.71M $4.11M $24.60M
2025 $15.65M -$369.6K $28.59M $9.59M $19.00M
2024 — -$15.49M $27.65M $10.16M $17.49M
2023 — -$21.38M $28.56M $6.55M $22.01M
Company Details
SIC code
2834
State of incorporation
C3
Active filer
Yes
Most recent SEC filing
Form DEFA14A
2026-09-18
Financials filed via
Form 10-K
filed 2026-09-18

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
Burlington, MA 01803
100 SUMMIT DR
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:33 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to Massachusetts — Public Companies